Phospho-EGF Receptor (Tyr845) Antibody

About the Target

Phospho-EGF(epidermal growth factor) Receptor (Tyr 845) is a transmembrane glycoprotein and a prototypical receptor tyrosine kinase widely expressed in epithelial tissues and frequently overexpressed in cancers such as breast and epidermoid carcinoma. Structurally, EGFR consists of an extracellular ligand-binding domain, a single transmembrane segment, and a cytoplasmic domain containing a kinase region with multiple regulatory tyrosine residues. Depending on the literature source, EGFR may also be discussed as Phospho-EGF Receptor (Tyr845).

Reported cellular context includes cell membrane, endoplasmic reticulum, endosome, and golgi apparatus, which can matter when signal is compared across treatments or changing cell states. Following EGFR across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

EGFR is commonly interpreted in the context of cancer and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane, endoplasmic reticulum, and endosome, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell membrane, endoplasmic reticulum, and endosome across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation
• differences between total target abundance and site-specific regulation when modified forms are compared

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for EGFR. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in EGFR reflect biology rather than handling. When interpreting EGFR, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep EGFR trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.